Cargando…
Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons
Background: Drug-coated balloons (DCBs), which deliver anti-proliferative drugs with the aid of excipients, have emerged as a new endovascular therapy for the treatment of peripheral arterial disease. In this study, we evaluated the use of keratose (KOS) as a novel DCB-coating excipient to deliver a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180741/ https://www.ncbi.nlm.nih.gov/pubmed/32244375 http://dx.doi.org/10.3390/molecules25071596 |
_version_ | 1783525889157365760 |
---|---|
author | Goel, Emily Erwin, Megan Cawthon, Claire V. Schaff, Carson Fedor, Nathaniel Rayl, Trevor Wilson, Onree Christians, Uwe Register, Thomas C. Geary, Randolph L. Saul, Justin Yazdani, Saami K. |
author_facet | Goel, Emily Erwin, Megan Cawthon, Claire V. Schaff, Carson Fedor, Nathaniel Rayl, Trevor Wilson, Onree Christians, Uwe Register, Thomas C. Geary, Randolph L. Saul, Justin Yazdani, Saami K. |
author_sort | Goel, Emily |
collection | PubMed |
description | Background: Drug-coated balloons (DCBs), which deliver anti-proliferative drugs with the aid of excipients, have emerged as a new endovascular therapy for the treatment of peripheral arterial disease. In this study, we evaluated the use of keratose (KOS) as a novel DCB-coating excipient to deliver and retain paclitaxel. Methods: A custom coating method was developed to deposit KOS and paclitaxel on uncoated angioplasty balloons. The retention of the KOS-paclitaxel coating, in comparison to a commercially available DCB, was evaluated using a novel vascular-motion simulating ex vivo flow model at 1 h and 3 days. Additionally, the locoregional biological response of the KOS-paclitaxel coating was evaluated in a rabbit ilio-femoral injury model at 14 days. Results: The KOS coating exhibited greater retention of the paclitaxel at 3 days under pulsatile conditions with vascular motion as compared to the commercially available DCB (14.89 ± 4.12 ng/mg vs. 0.60 ± 0.26 ng/mg, p = 0.018). Histological analysis of the KOS–paclitaxel-treated arteries demonstrated a significant reduction in neointimal thickness as compared to the uncoated balloons, KOS-only balloon and paclitaxel-only balloon. Conclusions: The ability to enhance drug delivery and retention in targeted arterial segments can ultimately improve clinical peripheral endovascular outcomes. |
format | Online Article Text |
id | pubmed-7180741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71807412020-05-01 Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons Goel, Emily Erwin, Megan Cawthon, Claire V. Schaff, Carson Fedor, Nathaniel Rayl, Trevor Wilson, Onree Christians, Uwe Register, Thomas C. Geary, Randolph L. Saul, Justin Yazdani, Saami K. Molecules Article Background: Drug-coated balloons (DCBs), which deliver anti-proliferative drugs with the aid of excipients, have emerged as a new endovascular therapy for the treatment of peripheral arterial disease. In this study, we evaluated the use of keratose (KOS) as a novel DCB-coating excipient to deliver and retain paclitaxel. Methods: A custom coating method was developed to deposit KOS and paclitaxel on uncoated angioplasty balloons. The retention of the KOS-paclitaxel coating, in comparison to a commercially available DCB, was evaluated using a novel vascular-motion simulating ex vivo flow model at 1 h and 3 days. Additionally, the locoregional biological response of the KOS-paclitaxel coating was evaluated in a rabbit ilio-femoral injury model at 14 days. Results: The KOS coating exhibited greater retention of the paclitaxel at 3 days under pulsatile conditions with vascular motion as compared to the commercially available DCB (14.89 ± 4.12 ng/mg vs. 0.60 ± 0.26 ng/mg, p = 0.018). Histological analysis of the KOS–paclitaxel-treated arteries demonstrated a significant reduction in neointimal thickness as compared to the uncoated balloons, KOS-only balloon and paclitaxel-only balloon. Conclusions: The ability to enhance drug delivery and retention in targeted arterial segments can ultimately improve clinical peripheral endovascular outcomes. MDPI 2020-03-31 /pmc/articles/PMC7180741/ /pubmed/32244375 http://dx.doi.org/10.3390/molecules25071596 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Goel, Emily Erwin, Megan Cawthon, Claire V. Schaff, Carson Fedor, Nathaniel Rayl, Trevor Wilson, Onree Christians, Uwe Register, Thomas C. Geary, Randolph L. Saul, Justin Yazdani, Saami K. Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons |
title | Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons |
title_full | Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons |
title_fullStr | Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons |
title_full_unstemmed | Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons |
title_short | Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons |
title_sort | pre-clinical investigation of keratose as an excipient of drug coated balloons |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180741/ https://www.ncbi.nlm.nih.gov/pubmed/32244375 http://dx.doi.org/10.3390/molecules25071596 |
work_keys_str_mv | AT goelemily preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT erwinmegan preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT cawthonclairev preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT schaffcarson preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT fedornathaniel preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT rayltrevor preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT wilsononree preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT christiansuwe preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT registerthomasc preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT gearyrandolphl preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT sauljustin preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons AT yazdanisaamik preclinicalinvestigationofkeratoseasanexcipientofdrugcoatedballoons |